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Chronic diseases are associated with patients’ long-term stress and development of fear to
things related to the source of stress. Better management of a patients’ condition requires
investigation of the underlying mechanisms that contribute to the process of development of
chronic stress. Multiple Sclerosis (MS) is a debilitating chronic disease in most cases
diagnosed after a relapse and characterized by the periodic occurrence of relapses in most
patients. Due to the unpredictable course of the disease and relapses, patients with
Relapsing-Remitting MS (RRMS) may deal with the stress of anticipation of relapse and its
unpredictable consequences. The role of relapses and related stress on patients’ quality of life
has not been previously investigated. This study is the first effort to develop a self-report
measure of Fear of Relapse (FoR) in patients with RRMS. Thirty-one items were extracted
from in-depth clinical interviews with 33 RRMS patients to develop the preliminary version of
the scale. Subsequently, 168 RRMS patients completed the questionnaire, the Intolerance of
Uncertainty Scale (IUS) and Depression, Anxiety, and Stress Scale (DASS). Fifty-one patients
completed the scale onemore time amonth later. Factor analysis revealed three components,
and five items failed to load on any of them. To test the FoR’s independence from similar
measures, responses to 26 items were pooled once with DASS items and once with IUS
items, and each time were subjected to confirmatory factor analysis (two-component
solution). Despite significant correlations between FoR, DASS, and IUS Independent
loadings of items belonging to FoR and DASS, and FoR and IUS revealed independence
and unique contribution of FoR to the evaluation of patients. Cronbach’s alpha for the 26-item
version was 0.92. Test-retest reliability for total score was equal to 0.74. These findings
provide preliminary evidence of the validity and reliability of the measure. This scale can help
researchers and clinicians to have a more comprehensive understanding of patients’g March 2020 | Volume 11 | Article 2261
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this stressor by targeting the underlying mechanism.Keywords: fear, relapse, scale development, psychometric properties, Relapsing-Remitting multiple sclerosisINTRODUCTION
Multiple sclerosis is a chronic and potentially debilitating disease
of the nervous system that affects people of all ages. Early
symptoms vary and may depend on one’s age, life history, and
other factors. Diagnosis normally follows the first major
occurrence of sub-acute neurological symptoms, which include
but are not limited to vision problems, sensory-motor deficits,
fatigue, balance problems, and dizziness. The progress of the
disease depends on many factors based on which the disease
phenotype can be divided into three subgroups, Relapsing-
Remitting MS (RRMS), Secondary-Progressive MS (SPMS),
and Primary-Progressive MS (PPMS). The course of the
disease is unpredictable for individuals, but the majority of
patients manifest the relapsing phenotype (85% RRMS) (1).
The relapses emerge as neurological events, which may be
similar to the first attack after which the disease was
diagnosed, or they might be completely different as new areas
of the nervous system become involved. The underlying
mechanism in the relapsing phenotype is the active
inflammation and subsequent demyelination in the Central
Nervous System (CNS). These relapses have short and long-
term consequences and might lead to the accumulation
of disability.
Many previous studies have shown that anxiety is an
inseparable part of life in patients with chronic diseases (2).
Fear is at the core of anxious thought of patients with chronic
diseases, and the source of fear depends on the underlying
condition. For example, in chronic pain, fear of pain is due to
the patient’s expectations about the influence of pain on his/her
personal and social life and how long-term pain causes disability
in both (3). Fear of progression has been found to be the pillar of
the anxiety problems of patients suffering from chronic diseases
like cancer and diabetes mellitus (4–6). A previous effort to
develop a tool for measuring fear of progression in chronically ill
patients resulted in FoP-Q, which has been shown to have proper
psychometric properties (5).
A source of anxiety in the relapsing stages of multiple sclerosis
is the relapse itself. Patients diagnosed with these phenotypes do
not know when they might have their next relapse and do not
have any estimation about the severity of the relapse and its
consequences. Generally, it is well-accepted that a new relapse is
a sign of disease activity and has its implications such as
treatment failure or accumulation of disability. It has also been
suggested that fear of progression (as an emotional response) is
related to the depression observed in patients with MS while it is
not correlated with gender, age, disease duration, and the stage of
the disease (7).
Individual prognosis differs among patients with MS. This
diversity is partly related to the phenotype and the diseaseg 2duration, but these alone fail to explain the observed variation.
It is important to realize that each MS phenotype is characterized
by specific complications and stressors, albeit the fact that
demyelination in the CNS might be present throughout the
course (8). Any tool that wants to give a clear image in such a
clinically diverse disease course must consider these differing
stressors. Existing self-report measures describing the
psychological impacts of MS on patients are limited in this
regard. It has been suggested that both psychological and
pharmaceutical interventions are necessary to improve the
quality of life in patients with MS (9). The measures that can
assess the fear related to the disease activity and the relapses are
paramount as they enable evaluating the efficiency of the
proposed interventions. We firstly aimed to develop a new tool
to measure the fear of relapse in patients with RRMS. Secondly,
we aimed to investigate the psychometric properties of this
measure in an independent sample of patients.METHOD
Diagnosis of MS in this study is done by a neurologist and based
on the 2010 revision of McDonald Criteria (10).
Interviews and Item Extraction
A semi-structured in-depth interview was conducted with 33
(18 females, age between 24–47 years, mean age = 33.18 ± 6.2
years; disease duration between 3 and 8 years, mean diseases
duration = 6.71 ± 3.3 years) patients with RRMS. All the
interviews were conducted by the same person (N.R.). Patients
were recruited from Sina specialized MS research and treatment
center, Tehran, Iran. For all patients, Persian was their native
language, and they had received their diagnosis in the previous
five years. They were all receiving disease-modifying treatments.
Expanded Disability Status Scale score for all these patients was
below 4. The study was approved by the ethics committee of the
department of psychology at Shahid Beheshti University, and all
subjects gave written consent prior to their participation.
The interview was based on pre-selected questions in four
main domains: (i) demographics and daily life experiences and
difficulties, (ii) cognitive problems, (iii) psychological problems,
(iv) social challenges. The interviews took 60 min at most. The
sessions were audio-recorded and transcripted afterward and
ATLAS.TI-6 was used for the organizat ion of the
interview material.
A number of keywords that the literature suggested for
individuals’ fear of relapse in MS were selected. This list
included: physical difficulties, stress, anxiety, relapse,
hospitalization, disease progress, fear, worries, and health
problems. A total number of 156 statements were found toMarch 2020 | Volume 11 | Article 226
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items was reviewed by three independent experts and those with
similar statements, unclear complaints, and non-relevant content
were removed and summarized. The final list contained 31 items
judged by their clarity, difficulty in understanding, and relevance.
Each item described the patient’s thoughts about symptoms that
could be associated with relapse or its consequences. A patient
would be asked to mention the degree to which these thoughts
came to his/her mind on a five-point Likert scale (0 = Never, 1 =
Rarely, 2 = Sometimes, 3 = Often, 4 = Always). The pre-final
version of the scale was presented to 10 patients, and their
understanding of each item was discussed. We also checked the
items with neurologists with expertise in MS and also with
psychologists with a focus on the treatment of patients with
chronic diseases. As a result, the wording of a few items was
adjusted to increase the understandability of them.
An English translation of items is provided in the tables in this
article. Items were translated from Persian to English by a bilingual
expert, and then back-translated from English to Persian by an
independent, experienced translator. Items of the original Persian
version and the back-translated items were compared, and the
translation of a few items was adjusted accordingly.
Psychometric Evaluation
Participants
A total number of 168 patients with RRMS (142 females; age 17–
57 years; mean = 32.65 ± 8.2) were recruited from multiple
centers (Golbooteh Omid charity center, Firoozgar hospital, Sina
MS research center) in Tehran, Iran, through convenience
sampling method. The duration of the disease (since the initial
diagnosis by a specialist) was between 0.5 and 5 years (mean =
3.19 ± 1.5) and the patients experienced between 1 and 9 relapses
(mean = 3.19 ± 2.2). The last major relapse that resulted in
receiving corticosteroid treatment was between 1 and 37 months
ago (mean = 12.42 ± 10.6). These patients received either a paper
version of the questionnaire or a link to the online version. There
was no difference in the outcome of self-report measures and
demographics between the groups that completed the paper or
the online version. The study was approved by the ethics
committee of the Department of Psychology at Shahid
Beheshti University and participants had given informed
consent prior to participation. For participants younger than
18 years consent was obtained from one of their parents.
Other Self-Report Measures
The following measures have consistently used in the literature of
research on patients with chronic disease to capture the general
anxiety and anxiety of an unpredictable future. We included
them to test the construct validity of our measure.
Depression Anxiety Stress Scale (DASS-21)
DASS-21 (11) is a self-report measure of depression, anxiety, and
stress among clinical and nonclinical populations and is reported
to have good to excellent psychometric properties in different
settings and populations (12, 13). Each item comprises a
statement about feelings and experiences that the reader had to
select to what degree it applied to them in the past week on aFrontiers in Psychiatry | www.frontiersin.org 3four-point Likert scale (0 = Did not apply to me at all; 3 =
Applied to me very much, or most of the time). This measure and
the 42 item variant has been translated to Persian and is widely
used in different studies and has shown good to excellent
psychometric properties [Cronbach’s alpha >0.8; (14, 15)].
Intolerance of Uncertainty (IUS-27)
IUS-27 (16) is a self-report measure, with 17 items describing
people’s reactions to uncertainties in life. Subjects have to rate
each item on a five-point Likert scale (1 = Not at all characteristic
of me; 5 = Entirely characteristic of me). This measure is
suggested to capture the fear of the unknown and anxiety
related to that and is proved to have good psychometric
properties (17). This measure has a two-factor structure that is
also considered in scoring: a factor that express unfairness of
beliefs related to the uncertainty about future and another factor
with items about the behavioral and self-referent implications of
uncertainty. The Persian version of this scale is widely used in
different settings and is showed to have good psychometric
properties (internal reliability = 0.88) (18).
Procedure
After receiving information about the nature of the research and
the aim of the current study, participants received either the
paper copy of the study or a link to complete the questionnaire
online. Fifty-one patients agreed to complete the questionnaire
one month later to test the reliability of the measure. The
Intolerance of Uncertainty measure, which has been suggested
to capture the fear of unknown happening, has been selected to
test the construct validity of the fear of relapse measure. For all
analyses, the statistical significance level was set to p < 0.05.RESULTS
Statistical Analysis
The frequency and percentage and number of missing responses
for each item has been reported. Each item’s correlation with the
total score and the Cronbach’s alpha coefficient has been
calculated for all items to study the internal consistency of the
measure. Correlation analysis between FoR’s score and DASS
and IUS was calculated to test the external validity of the scale.
The test-retest reliability has been examined using a Spearman
Correlation. A Bland-Altman plot (Figure 1) was used to display
the difference between two times FoR completion and against the
average of them. Confirmatory Factor analysis has been hired to
examine the internal validity of the scale. To test the external
validity and for the convergent validity, the correlation between
FoR, DASS, and IUS has been reported. For the discriminant
validity, pooled item factor analysis has been performed and the
average variance extracted was compared to the square
of correlation.
Depression, Anxiety, and Stress
Based on the DASS scores, patients’ depression was between 0
and 20 with the mean = 8.30 ± 6.0 which is in normal range.March 2020 | Volume 11 | Article 226
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analysis. Anxiety was between 0 and 14 with the mean = 6.90 ± 4.4
which is in normal range. None of patients had severe anxiety and
was not excluded from analysis. Stress was between 1 and 21 with
the mean = 10.86 ± 5.3 which is in normal range. None of patients
had severe stress and was not excluded from analysis.
Properties of the Fear of Relapse Scale
Responses to 31 items of the Fear of Relapse Scale are
summarized in Table 1. Total FoR score were between 0 and
113 (mean = 41.6, SD = 21.1). The total score did not follow a
normal distribution and showed skewness to the right. In
addition, there was no correlation between the FoR total score
and the duration of the disease or the number of relapses or time
since their last relapse.
Internal Consistency
Each item was correlated with the total score with a correlation
value greater than 0.366 (ps <0.001) (Table 2). Cronbach’s Alpha
was equal to 0.924.
Test-Retest Reliability
Spearman’s rank coefficient was selected to measure test-retest
reliability for items independently. All items showed a high
correlation (Spearman’s rank coefficients ranged from 0.349 to
0.815 [ps < 0.05]). A Pearson correlation conducted to measure
the test-retest reliability of the total score showed to be significant
0.74 (p < 0.001). Table S1 presents results of the test-retest
correlation analysis. Figure 1 presents the Bland-Altman plot.
The difference between two times completion of the FoR isFrontiers in Psychiatry | www.frontiersin.org 4ranged between 28 and −20 (average 3.45 ± 12.98). All the
differences fall within 95% confidence of interval from the mean.
Regression analysis with the difference score as the dependent
variable and the mean of two times completions as the predictor
suggest that there is no proportional bias against the mean (t =
−0.927; p = 0.36).
Factor Analysis
A Principal axis factor with Varimax rotation of item from the
Fear of Relapse Scale was conducted on the data gathered from
patients with RRMS. An examination of the Kaiser-Meyer Olkin
measure of sampling adequacy suggested that the sample was
factorable (KMO = 0.851; p < 0.001).
The results of an orthogonal rotation of the solution are
shown in Table 3. When rotated factors items with loadings less
than 0.45 were excluded, the analysis yielded a three-factor
solution (five items have been suggested to be removed: 1, 24,
26, 30, 31). Only one item (#27) was loaded on two components.
Table 3 presents the result of the factor analysis. Cronbach’s
Alpha after removal of the five items mentioned above went
down from 0.924 to 0.917.
Validity
To test conduct validity of the Fear of Relapse Scale we used a
Pearson correlation analysis to examine the correlation between
the Fear of Relapse Scale (total score after removing five items,
three components as the result of factor analysis) and IUS score
on two factors and DASS subscales (Depression, Anxiety, Stress).
Table 4 presents the result of the correlation analysis. All the
correlations were significant (ps < 0.001).FIGURE 1 | Bland-Altman plot: differences between two times completion of the Fear of Relapse (FoR) Scale by the average of the two scores. Dotted lines indicate
the interval that includes 95% of differences between the first and the second assessment.March 2020 | Volume 11 | Article 226
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items of the FoR and DASS items (principal components,
varimax rotation, maximum iterations for convergence = 50,
excluding values below 0.35) resulted in a clear separation of two
scales on two components. For the DASS only items 4, 15, and 19
weighted below 0.35, and for the FoR, only item 20 weighted
below 0.35. For the DASS items 3, 5, and 15 loaded on both
components while the weight on the first component related to
other DASS items (respectively 0.615, 0.592, 0.707) was much
higher than the weight for on the second component related to
FoR items (respectively 0.358, 0.376, 0.353). For the FoR, only
the item numbered 16 loaded on both components, while the
weight for the second component related to FoR items (0.418)
was higher than the weight on the first component (0.415). The
average variance extracted for both FoR and DASS (0.702) is
higher than the square of correlation between FoR and DASS
(0.589). Hence discriminant validity is established.
A similar analysis using the IUS items instead of the DASS
resulted in a clear separation of two scales on two components.
For this analysis, only the item numbered 20 of the FoR weighted
below 0.35 and was removed. Besides, only two IUS items (1 and
7) were loaded on both components. Both items were loaded on
the first component (along with other IUS items; respectively
0.438, 0.608) higher than the second component related (along
with FoR items; respectively 0.397, 0.393). The average variance
extracted for both FoR and IUS (0.637) is higher than the squareFrontiers in Psychiatry | www.frontiersin.org 5of correlation between FoR and IUS (0.498). Hence discriminant
validity is established.DISCUSSION
The most common phenotype of MS known as relapsing-
remitting MS appears in the form of unpredictable relapses
that are associated with the progression of the disease and may
result in irreversible damages to the sensations and functions of a
person. Like other chronic diseases, fear of consequences,
worsening, and relapse is a dominant part of MS as well. The
nature of fear and the source of fear have not been investigated
very well in the literature on MS. Only a few studies compared
the patients’ fear of falling between different age groups of MS
patients (19). Understanding and the management of fear in
chronic diseases have been suggested to be associated with the
improvement in self-management in patients (20). Consequently,
improved self-management in chronic disease has been suggested to
be associated with an improvement in health status, increase in self-
efficacy, and a reduction in hospitalization (21). Thus, increased self-
management of a chronic disease reduces the economic and
emotional burden of the disease and might result in a substantial
increase in the quality of life of patients with chronic illnesses (22).
Relapses in MS with unknown course and severity are a big source
of anxiety in patients and contribute to the development of fear inTABLE 1 | Number of responses for all items of the fear of relapse scale (percentage).
Items Never Rarely Sometimes Often Always Missing
1. I feel another relapse is about to happen whenever I get red eyes or feel pain behind my eyes. 73 (43.5) 42 (25) 28 (16.7) 15 (8.9) 9 (5.4) 1
2. Another relapse means another hospitalization 61 (36.3) 28 (16.7) 41 (24.4) 17 (10.1) 19 (11.3) 2
3. My appearance gives away the fact that I am experiencing a relapse. 68 (40.5) 38 (22.6) 33 (19.6) 16 (9.5) 10 (6) 3
4. Each relapse means the disease is spreading in the nervous system. 34 (20.2) 40 (23.8) 52 (31) 25 (14.9) 13 (7.7) 4
5. I do a lot of exercises because I am afraid of experiencing a relapse. 67 (39.9) 41 (24.4) 28 (16.7) 19 (11.3) 12 (7.1) 1
6. I don’t drive in fear of a relapse. 111 (66.1) 11 (6.5) 14 (8.3) 9 (5.4) 21 (12.5) 2
7. Whenever a relapse happens, it can only be managed with more corticosteroids. 57 (33.9) 23 (13.7) 35 (20.8) 26 (15.5) 25 (14.9) 2
8. The disease will come back in the form of a relapse if I stop taking medication for one month. 50 (29.8) 34 (20.2) 32 (19) 17 (10.1) 32 (19) 3
9. Each relapse takes me one step closer to becoming bedridden. 52 (31) 37 (22) 38 (22.6) 24 (14.3) 17 (10.1) 0
10. Each relapse will make me more dependent on other people. 48 (28.6) 33 (19.6) 29 (17.3) 29 (17.3) 28 (16.7) 1
11. Thinking about relapses makes my heart jitter. 42 (25) 35 (20.8) 40 (23.8) 27 (16.1) 23 (13.7) 1
12. After each relapse, I put all my task and duties aside. 60 (35.7) 49 (29.2) 33 (19.6) 16 (9.5) 8 (4.8) 2
13. A severe relapse with strong symptoms can result in death. 115 (68.5) 24 (14.3) 20 (11.9) 6 (3.6) 3 (1.8) 0
14. Any experience of numbness and tingling in my limbs means I am having another relapse. 47 (28) 51 (30.4) 40 (23.8) 17 (10.1) 13 (7.7) 0
15. Heat can trigger a relapse. 26 (15.5) 39(23.2) 39 (23.2) 38 (22.6) 26 (15.5) 0
16. Relapses cause memory decline. 47 (28) 31 (18.5) 44 (26.2) 30 (17.9) 14 (8.3) 2
17. Relapses cause loss of control over movement and posture stability. 32 (19) 36 (21.4) 39 (23.2) 36 (21.4) 24 (14.3) 1
18. When I think about relapse, I am unable to think about anything else. 43 (25.6) 47 (28) 29 (17.3) 21 (12.5) 25 (14.9) 3
19. Grave news can trigger a relapse. 20 (11.9) 33 (19.6) 54 (32.1) 39 (23.2) 20 (11.9) 2
20. Due to fear of a sudden relapse, I try not to take a shower when I am home alone. 143 (85.1) 13 (7.7) 6 (3.6) 3 (1.8) 3 (1.8) 0
21. Relapses worsen the level of fatigue I feel. 25 (14.9) 27 (16.1) 46 (27.4) 38 (22.6) 31 (18.5) 1
22. Relapses can cause urine and stool incontinence. 78 (46.4) 27 (16.1) 33 (19.6) 18 (10.7) 8 (4.8) 4
23. I try not to go out much due to the fear of experiencing a sudden relapse. 118 (70.2) 13 (7.7) 18 (10.7) 11 (6.5) 6 (3.6) 2
24. Thinking about the disease decreases my libido significantly. 83 (49.4) 28 (16.7) 28 (16.7) 13 (7.7) 15 (8.9) 1
25. I don’t accept new tasks due to fear of relapses. 97 (57.7) 20 (11.9) 23 (13.7) 18 (10.7) 8 (4.8) 2
26. A bad headache can be a sign of a sudden relapse. 64 (38.1) 51 (30.4) 30 (17.9) 11 (6.5) 9 (5.4) 3
27. Whenever I drop anything, I think I am about to have a relapse. 69 (41.1) 41 (24.4) 27 (16.1) 19 (11.3) 12 (7.1) 0
28. The thought of experiencing a relapse makes me cry. 67 (39.9) 27 (16.1) 22 (13.1) 19 (11.3) 32 (19) 1
29. Not knowing when the next relapse is going to happen is very annoying to me. 83 (49.4) 24 (14.3) 18 (10.7) 17 (10.1) 24 (14.3) 2
30. I think increased sensitivity to exercises or tastes can be a sign of relapse. 129 (76.8) 21 (12.5) 10 (6) 6 (3.6) 2 (1.2) 0
31. Blurred vision or double vision can be a sign of relapse. 16 (9.5) 26 (15.5) 45 (26.8) 41 (24.4) 40 (23.8) 0March 2020 | Volume 11 | Article 226
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Item Item-total correlation Score (mean ± SD)
1. I feel another relapse is about to happen whenever I get red eyes or feel pain behind my eyes. .366** 1.07 (1.2)
2. Another relapse means another hospitalization .541** 1.43 (1.4)
3. My appearance gives away the fact that I am experiencing a relapse. .521** 1.16 (1.2)
4. Each relapse means the disease is spreading in the nervous system. .594** 1.65 (1.2)
5. I do a lot of exercises because I am afraid of experiencing a relapse. .370** 1.21 (1.3)
6. I don’t drive in fear of a relapse. .453** 0.9 (1.5)
7. Whenever a relapse happens, it can only be managed with more corticosteroids. .564** 1.63 (1.5)
8. The disease will come back in the form of a relapse if I stop taking medication for one month. .601** 1.68 (1.5)
9. Each relapse takes me one step closer to becoming bedridden. .622** 1.51 (1.3)
10. Each relapse will make me more dependent on other people. .575** 1.74 (1.5)
11. Thinking about relapses makes my heart jitter. .686** 1.72 (1.4)
12. After each relapse, I put all my task and duties aside. .583** 1.17 (1.2)
13. A severe relapse with strong symptoms can result in death. .428** 0.56 (1)
14. Any experience of numbness and tingling in my limbs means I am having another relapse. .513** 1.39 (1.2)
15. Heat can trigger a relapse. .371** 1.99 (1.3)
16. Relapses cause memory decline. .548** 1.6 (1.3)
17. Relapses cause loss of control over movement and posture stability. .664** 1.9 (1.3)
18. When I think about relapse, I am unable to think about anything else. .742** 1.62 (1.4)
19. Grave news can trigger a relapse. .635** 2.04 (1.2)
20. Due to fear of a sudden relapse, I try not to take a shower when I am home alone. .305** 0.27 (0.8)
21. Relapses worsen the level of fatigue I feel. .623** 2.14 (1.3)
22. Relapses can cause urine and stool incontinence. .453** 1.09 (1.2)
23. I try not to go out much due to the fear of experiencing a sudden relapse. .499** 0.64 (1.1)
24. Thinking about the disease decreases my libido significantly. .497** 1.1 (1.3)
25. I don’t accept new tasks due to fear of relapses. .559** 0.92 (1.3)
26. A bad headache can be a sign of a sudden relapse. .475** 1.09 (1.2)
27. Whenever I drop anything, I think I am about to have a relapse. .609** 1.19 (1.3)
28. The thought of experiencing a relapse makes me cry. .622** 1.53 (1.6)
29. Not knowing when the next relapse is going to happen is very annoying to me. .650** 1.25 (1.5)
30. I think increased sensitivity to exercises or tastes can be a sign of relapse. .298** 0.4 (0.8)
31. Blurred vision or double vision can be a sign of relapse. .460** 2.38 (1.3)Frontiers in Psychiatry | www.frontiersin.org 6 March 2020 | VoTABLE 3 | Item factor loading for the final solution on 26 final items of the Fear of Relapse Scale.
Item Component
1 2 3
2. Another relapse means another hospitalization 0.75
9. Each relapse takes me one step closer to becoming bedridden. 0.719
10. Each relapse will make me more dependent on other people. 0.712
11. Thinking about relapses makes my heart jitter. 0.694
7. Whenever a relapse happens, it can only be managed with more corticosteroids. 0.663
18. When I think about relapse, I am unable to think about anything else. 0.651
4. Each relapse means the disease is spreading in the nervous system. 0.615
12. After each relapse, I put all my task and duties aside. 0.564
28. The thought of experiencing a relapse makes me cry. 0.547
8. The disease will come back in the form of a relapse if I stop taking medication for one month. 0.543
29. Not knowing when the next relapse is going to happen is very annoying to me. 0.542
27. Whenever I drop anything, I think I am about to have a relapse. 0.495 0.495
3. My appearance gives away the fact that I am experiencing a relapse. 0.488
16. Relapses cause memory decline. 0.713
14. Any experience of numbness and tingling in my limbs means I am having another relapse. 0.659
15. Heat can trigger a relapse. 0.64
21. Relapses worsen the level of fatigue I feel. 0.629
17. Relapses cause loss of control over movement and posture stability. 0.562
19. Grave news can trigger a relapse. 0.544
22. Relapses can cause urine and stool incontinence. 0.496
13. A severe relapse with strong symptoms can result in death. 0.486
23. I try not to go out much due to the fear of experiencing a sudden relapse. 0.714
5. I do a lot of exercises because I am afraid of experiencing a relapse. 0.708
6. I don’t drive in fear of a relapse. 0.61
20. Due to fear of a sudden relapse, I try not to take a shower when I am home alone. 0.597
25. I don’t accept new tasks due to fear of relapses. 0.531lume 11 | ArticFive items with loading weights below 0.45 were removed from the table and the final version of the scale.le 226
Khatibi et al. Fear of Relapse Scale in RRMSpatients (23). However, as far as we are aware, fear of relapse and its
impacts on the quality of life has not been fully addressed, and we
need to develop a scale to screen MS patients. Measuring fear of
relapse may help the health care system to treat patients in a more
personalized approach. As such, the current study aimed to develop
a measure that can quantify fear of relapse in patients suffering
relapsing-remitting MS and to validate it in a separate sample
of participants.
To test the validity of the Fear of Relapse Scale, the patients
were asked to complete two other measures assessing their
intolerance of uncertainty (fear of unknown) and stress,
anxiety, and depression. Both scales and all subscales were
significantly and positively correlated with individuals’ total
fear of relapse score. The Pearson correlation was at medium
range suggesting a relationship between the FoR scale, DASS,
and IUS measures. Further investigations, however, showed that
when two independent two-components factor analyses were
run by pooling items of the Fear of Relapse Scale once with the
IUS and once with the DASS, items related to each scale were
independently loaded on a separate component, which suggest
that in spite of a positive and significant correlation, each of the
included measures assess independent constructs. This suggests
that inclusion of the fear of relapse in research and clinical work
with MS patients can capture characteristics in patients that
cannot solely be explained by intolerance of uncertainty,
depression, anxiety, and stress in patients.
We tested the reliability based on test-retest and internal
consistency, Cronbach’s Alpha. The Cronbach’s alpha for the
scale was 0.94, which is above the suggested threshold for the
assessment of reliability (24). In line with this analysis, all items
in the measure were positively and significantly correlated with
the total score of the scale, which indicates the high internal
consistency of the Fear of Relapse Scale (25). Furthermore, the
test-retest reliability showed a high positive and significant
correlation between each item’s score in the test and that
item’s score in the retest. Above that, the total score of test-
retest reliability showed a high, positive correlation (>0.7).
Similarly, the Bland-Altman analysis and the plot indicated
that there is a high level of agreement between two times
completion of the scale and there is no trend or proportional
bias in differences between two times completion of the scale. It is
important to remember that none of the patients experienced a
relapse or any major problem related to their disease within the
period between two assessments. Putting these results together it
can be suggested that the Fear of Relapse Scale is a reliable
measure, but further studies with long-term follow-up of patientsFrontiers in Psychiatry | www.frontiersin.org 7are required to examine the ability of the scale to capture changes
due to the alterations in the condition of the patient.
A principal component analysis of all 31 original items of the
Fear of Relapse Scale resulted in the removal of 5 items and the
remaining 26 items loaded on three factors. The first factor includes
items that refer to the fear of disability following a relapse. Disability
is a concern for many patients who receive MS diagnosis. The link
between the experience of relapse and the progress of the disease
causes patients to see each relapse as another step towards the
disability, and this can result in the experience of excessive
hypervigilance and fear of relapse. The second factor includes
items related to the fear of the psychological and physiological
consequences of a relapse. The difference between this component
and the previous one is in the understanding of the fact that
disability is not the sole outcome of the disease and relapses. A
relapse may cause a lot of secondary problems, which can interfere
with the life of the patient, and items in the second component
target these aspects. Usually, relapses are followed by short-term (or
in some cases an irreversible) losses in the function of the sensory
andmotor systems in the central nervous system. Uncertainty about
the prognosis of the sensory and motor losses and the future of
patients’ functions is another source of stress feeding their fear of
relapse. The third factor includes items indicating limitations
resulting from fear. After the diagnosis, many patients become
hypervigilant to the potential impact of the disease on their abilities
and thus, they may start to withdraw from many activities and stop
accepting new challenges. This avoidance may contribute to the
development of fear and further disability and lowering self-efficacy.
Compared to the other two components, this component relates to
the meta-cognition of patients about the existence of fear and its
influence on their life.
Fear of relapse in MS is a neglected phenomenon in the
studies investigating the psychological aspects of the diagnosis
and living with MS. Psychological factors play a crucial role in
the quality of life in patients with MS especially due to the
chronic nature of the disease (26). A better understanding of a
chronic disease requires a comprehensive approach to take
different components into account, especially when it comes to
the quality of life as a multi-dimensional aspect (27). A previous
attempt to develop measures related to the quality of life in MS
resulted in the PERSEPP scale (“PERception de la Sclérose En
Plaques et de ses Poussées”) (28). Five dimensions of that scale
target social support, relationship difficulties, fatigue, state of
mind and associated sleep disorders, and time perspective.
However, fear as a factor related to the understanding of the
patient’s acceptance of has not received in depth attention there.TABLE 4 | Correlations between Depression, Anxiety, Stress, Scale, Intolerance of Uncertainty Scale, Fear of Relapse Scale and its Subscales.
DASS_D DASS_A DASS_S IUS_F1 IUS_F2
FoR_total .600** .587** .588** .513** .527**
FoR_Comp1 .540** .497** .542** .491** .495**
FoR_Comp2 .521** .546** .520** .449** .458**
FoR_Comp3 .400** .422** .338** .316** .358**March 2020 | Volume 11 | ArDASS_D, Depression subscale of DASS; DASS_A, Anxiety subscale of DASS; DASS_S, Stress subscale of DASS; IUS_F1, Factor 1 of the Intolerance of Uncertainty Scale; IUS_F2, Factor
2 of the Intolerance of Uncertainty Scale.
**p < 0.001.ticle 226
Khatibi et al. Fear of Relapse Scale in RRMSUnderstanding the source of fear in MS patients will assist
professionals to grasp a more detailed image of their life to
provide more specific and effective interventions (29). It can be
suggested that interventions for the improvement of the fear of
relapse might be more effective if provided at the earlier stages of
the development of the disease (30).
However, this study has limitations too. The sample of
patients in the current study had varying disease duration.
Although we did not find any association between the duration
of the disease and fear of relapse scores, previous studies
suggested that the impact of psychological factors in the first
year following the diagnosis is stronger on the quality of life of
the patients (30). Also, RRMS patients vary greatly in earlier
clinical presentations in comparison with more chronic
progressive phenotype (31). Future studies with a larger
number of patients in their first year following the diagnosis
may help us to characterize fear of relapse among them and to
compare them with patients who have experienced more relapses
and have a longer disease duration. Besides, since the concept of
fear of relapse has not been well investigated in the literature,
future studies on a diverse group of patients will allow us to
examine the content validity of the measure in more detail. Also,
long-term follow-up of patients and changes in their FoR scores
can give us a more comprehensive image beside the test-retest
reliability. Furthermore, the original version of the scale was
developed in Persian. The English translation needs to be
investigated in English speaking populations. As such, the
measure should be the subject for future studies in another
language considering linguistic and cultural differences.
Taken together, this study presents a scale for the assessment of
the fear of relapse in RRMS patients. Our data provides preliminary
evidence of validity and reliability for this scale. The Fear of Relapse
Scale presented in this study showed good internal consistency and
high test-retest reliability. This measure needs to be tested in future
studies to contribute to the understanding of the life of the patients
suffering RRMS and may assist clinicians in identifying the specific
sources of anxiety in patients and helping them to plan their
interventions tailored to the clinical needs of the patient.Frontiers in Psychiatry | www.frontiersin.org 8DATA AVAILABILITY STATEMENT
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